Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy in the First-line Anti-Helicobacter Pylori Treatment
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Subjects with Helicobacter pylori infection
Locations
Other Locations
Taiwan
Kaohsiung Medical University Hospital
RECRUITING
Kaohsiung City
Contact Information
Primary
Deng-Chyang Wu, MD, PHD
dechwu@yahoo.com
88673121101
Time Frame
Start Date: 2025-10-21
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 552
Treatments
Active_comparator: bismuth-amoxicillin-vonoprazan triple therapy
vonoprazan 20mg twice a day +tripotassium dicitrate bismuthate 300mg four times a day +amoxicilline 750mg four times a day
Active_comparator: bismuth-based quadruple therapy
rabeprazole 20mg twice a day+ tripotassium dicitrate bismuthate 300mg four times a day+ tetracycline 500mg four times a day+ metronidazole 250mg four times a day
Related Therapeutic Areas
Sponsors
Leads: Kaohsiung Medical University
Collaborators: Kaohsiung Veterans General Hospital.